Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs.
Risks associated with the federal antikickback statute increased significantly for the pharmaceutical industry in the 1990s. Manufacturers, physicians, and MCOs must take account of the statute when developing programs that could possibly implicate it. This article provides guidance to the managed care community regarding legal kickback risks in arrangements with pharmaceutical manufacturers.
Simmer
W Scott
WS
Wright, Morris & Arthur, LLP, 1919 Pennsylvania Avenue, NW, Suite 500, Washington, DC 20006-3434, USA. ssimmer@porterwright.com
D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D011307:Drug Prescriptions / Q000191:economics*; D004502:Education, Medical, Continuing; D005607:Fraud / Q000331:legislation & jurisprudence* / Q000517:prevention & control; D006801:Humans; D008329:Managed Care Programs / Q000331:legislation & jurisprudence*; D012051:Reimbursement Mechanisms; D012308:Risk Management; D014481:United States